Facebook
Twitter
LinkedIn
Forward
New and Emerging Small Molecules: Making a Difference in UC (Archived CME/CE Webcast)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Ulcerative colitis (UC) is a chronic inflammatory condition of the colorectum that is challenging to control and substantially degrades patient-related quality of life. Although treatments for UC have expanded in recent decades, limitations related to their safety, tolerability, and practicality of administration exist. Therapeutic agents in the form of oral small molecule drugs are either recently approved or in development and represent breakthroughs in the treatment UC that are anticipated to bring a significant shift to the treatment paradigm. This webcast is a recording of a live symposium that took place on Sunday, May 22, 2022. (Note: Upadacitinib has since been approved by the US Food and Drug Administration for use in patients with moderate to severe UC. At the time of this educational activity’s release, etrasimod is under investigation for its use in UC.) The desired results of this activity are to educate gastroenterology clinicians on updates in the treatment and management of patients with UC.
Target Audience
This educational activity is intended for gastroenterologists, gastroenterology physician assistants, and nurse practitioners involved in the care of patients with ulcerative colitis.
Learning Objectives
After completing this activity, participants will be better able to:
- Review the mechanisms of action of small molecules for ulcerative colitis
- Describe features of oral small molecules for ulcerative colitis
- Summarize clinical evidence on small molecule drugs for ulcerative colitis
- Identify patients who would be good candidates for treatment with small molecule drugs
Faculty
 | Edward V. Loftus, Jr, MD (Chair)
|
 | Anita Afzali, MD, MPH, MHCM Professor of Medicine Executive Vice Chair Department of Internal Medicine Associate Chief Medical Officer University of Cincinnati UC Health System Cincinnati, Ohio |
 | Remo Panaccione, MD, FRCPC Professor of Medicine Director, Inflammatory Bowel Disease Group University of Calgary Calgary, Canada |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Anita Afzali, MD, MPH, MHCM, is a consultant for AbbVie Inc, Bristol-Myers Squibb Company, DiaSorin SpA, Eli Lilly and
Company, Janssen Pharmaceuticals, Inc, Pfizer Inc, Takeda Pharmaceuticals USA, Inc, and TLL Pharmaceuticals LLC.
Edward V. Loftus, Jr, MD, is a consultant for AbbVie Inc, Amgen Inc, Arena Pharmaceuticals, Inc, Boehringer Ingelheim
International GmbH, Bristol-Myers Squibb Company, CALIBR, Celgene Corporation, Eli Lilly and Company, Genentech, Inc,
Gilead, Iterative Scopes, Inc, Janssen Pharmaceuticals, Inc, Morphic Therapeutic, Ono Pharmaceutical Co, Ltd, Protagonist
Therapeutics Inc, Surrozen, Takeda Pharmaceuticals USA, Inc, and UCB SA; and is a contracted researcher for AbbVie Inc,
Alimentiv, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc, Gilead, Janssen Pharmaceuticals, Inc,
Pfizer Inc, Receptos, Takeda Pharmaceuticals USA, Inc, Theravance Biopharma, and UCB SA.
Remo Panaccione, MD, is a consultant for AbbVie Inc, Abbott, Alimentiv, Amgen Inc, Arena Pharmaceuticals, AstraZeneca,
Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare,
Cosmos Pharmaceuticals, Eisai Inc, Elan Pharmaceuticals, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ferring BV,
Galapagos NV, Genentech, Inc, Gilead, GlaxoSmithKline, JAMP Pharma, Janssen Pharmaceuticals, Inc, Merck & Co., Inc,
Oppilan Pharma Ltd, Pandion Therapeutics, Pfizer Inc, Progenity, Inc, Protagonist Therapeutics Inc, Satisfai Health, Inc, Sandoz
International GmbH, Schering-Plough Corporation, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals USA, Inc,
Theravance Biopharma, UCB SA, and Viatris Inc; is an advisory board member of AbbVie Inc, Amgen Inc, Arena
Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion Healthcare, Eli Lilly and Company, Ferring BV,
Fresenius Kabi USA, Galapagos NV, Genentech, Inc, Gilead, GlaxoSmithKline, JAMP Pharma, Janssen Pharmaceuticals, Inc,
Merck & Co., Inc, Oppilan Pharma Ltd, Organon, Pandion Therapeutics, Pfizer Inc, Sandoz International GmbH, Shire, Sublimity
Therapeutics, Theravance Biopharma, Takeda Pharmaceuticals USA, Inc, and Viatris Inc; is a contracted researcher for AbbVie
Inc, Ferring BV, Janssen Pharmaceuticals, Inc, Pfizer Inc, and Takeda Pharmaceuticals USA, Inc; is on the speakers bureau for
AbbVie Inc, Arena Pharmaceuticals, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ferring BV, Gilead,
Janssen Pharmaceuticals, Inc, Merck & Co., Inc, Pfizer Inc, Sandoz International GmbH, Shire, Takeda Pharmaceuticals USA, Inc, and Viatris; and is an independent contractor for AbbVie Inc, Janssen Pharmaceuticals, Inc, Pfizer Inc, and Takeda
Pharmaceuticals USA, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Satisfactory Completion
Learners must take the pretest, view the webcast, and complete the posttest and evaluation form to receive a certificate of completion. Your chosen session must be viewed in its entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
For Physicians
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Nurses
Interprofessional Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Arena Pharmaceuticals, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco LLC, or Arena Pharmaceuticals, Inc.
©2023 MedEdicus LLC. 268.2